In the 1980s, MDMA was largely known as a party drug. Dubbed “Ecstasy” on the street, it became a favorite at raves and nightclubs for the feelings of euphoria, energy, and deep connection it inspired. But long before it made its way onto dance floors—and long before it became a Schedule I controlled substance—MDMA was quietly helping people heal.
In Psychedelics A to Z, Dr. Olga Chernoloz devotes “X is for XTC” to the fascinating arc of MDMA’s cultural and medical journey. Synthesized in 1912 and left on the pharmaceutical shelf for decades, it was reintroduced in the 1970s by chemist Alexander Shulgin. After trying it himself, he shared it with a small network of therapists. What they found was remarkable.
MDMA helped patients open up, process painful memories, and speak honestly without becoming overwhelmed by fear or shame. In therapy sessions, it became a kind of emotional lubricant, easing communication and dissolving defensive walls. Therapists like Leo Zeff were so impressed that they made it a core part of their practice, using it legally until it was abruptly criminalized in 1985.
Why the ban? As MDMA’s popularity grew outside the therapy room, so did its visibility at parties and clubs. The DEA, spurred by concerns about recreational use and media panic, moved quickly to classify it as a dangerous and medically useless substance. Despite expert testimony urging regulation rather than prohibition, the decision stuck. MDMA joined the ranks of other banned psychedelics, and its therapeutic potential was largely buried, at least for a while.
Decades later, we’re seeing a dramatic reversal.
Today, MDMA is on the brink of becoming the first psychedelic to receive FDA approval as a prescription treatment. Thanks to the tireless work by organizations like MAPS (Multidisciplinary Association for Psychedelic Studies), a large body of clinical evidence now supports its use in treating post-traumatic stress disorder (PTSD). Patients who have struggled for years with trauma—many of them veterans, survivors of abuse, or first responders—have shown dramatic improvement after just a few sessions of MDMA-assisted therapy.
As Dr. Chernoloz explains, MDMA isn’t magic. It doesn’t erase trauma or offer a quick fix. But it does create the right conditions for healing. It reduces fear, heightens trust, and allows patients to confront painful experiences without becoming overwhelmed. It also enhances empathy and connection, deepening the therapeutic relationship.
Importantly, the clinical use of MDMA looks nothing like its party scene counterpart. Doses are carefully controlled. Sessions are conducted in calm, supportive environments. Therapists are trained not just in traditional methods, but in how to guide patients through altered states. And integration—the process of making sense of the experience afterward—is built into the model.
Dr. Chernoloz also addresses the risks. MDMA can have side effects, including short-term anxiety, sleeplessness, or a post-session “comedown.” Its purity is a concern in unregulated markets, where street drugs may be cut with harmful substances. But when used in clinical settings with proper support, the risk profile is surprisingly low—especially when compared to many current psychiatric medications.
What’s most striking in this story is not just the comeback of MDMA, but what it reveals about our evolving relationship with psychedelics. A substance once dismissed as dangerous and frivolous is now showing us new ways to treat some of the hardest-to-heal wounds.
In Psychedelics A to Z, the story of MDMA is both a cautionary tale and a beacon of hope. It reminds us that science, compassion, and persistence can undo decades of stigma—and that sometimes, the path to healing begins with seeing an old substance in a new light.
